Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Perspective Therapeutics Inc CATX

Healthcare Biotechnology
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that... see more

Recent & Breaking News (NYSEAM:CATX)

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

GlobeNewswire 2 days ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

GlobeNewswire 8 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

GlobeNewswire 11 days ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

GlobeNewswire October 31, 2024

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

GlobeNewswire October 29, 2024

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire October 23, 2024

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

GlobeNewswire October 16, 2024

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

GlobeNewswire October 11, 2024

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

GlobeNewswire October 10, 2024

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

GlobeNewswire October 7, 2024

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire September 30, 2024

Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024

GlobeNewswire September 10, 2024

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

GlobeNewswire September 5, 2024

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewswire August 28, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

GlobeNewswire August 12, 2024

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

GlobeNewswire July 30, 2024

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

GlobeNewswire July 22, 2024

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

GlobeNewswire June 12, 2024

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

GlobeNewswire June 11, 2024

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

GlobeNewswire June 10, 2024